Event Organizer

Welcome message

I would like to deliver my warm greetings and heartfelt welcome to all Participants of the International Cancer Proteogenomics Symposium. This workshop is designed to share the knowledge of cancer proteogenomics, and to facilitate the collaboration of researchers who are interested in the clinical applications of proteogenomic data.

In this century, the outcome of basic and clinical research in the last decades has led to remarkable progress in treatments, and the molecular targeted therapy, cancer genomic medicine and cancer immune therapy are widely used in the clincal practice. Multiple treatment options are available for single types of malignancies, and the patients with similar cancers demonstrate the different response to treatments. Therefore, we need modalities to capture the important characters of cancers for precise diagnosis, and optimize the therapeutic strateiges for individual cancer patients. Moreover, adequate therapeutic strategies are currently established only in the limited types of cancers, and novel therapy has long been desired for a considerable number of patients with rare cancers. More efforts will be requred for the patients who suffer from cancers. Cancer proteogenomics will offer the opportunities to develop novel diagnostic and therpeutic modalities.

The International Cancer Proteogenomics Symposium will welcome participants from the basic and clinical researchers in academia or industry. The meeting will provide an excellent opportunity to exchange and share a wide range of the ideas for cancer proteogenomics toward clinical applications. The Symposium will promote the international collaboration and cooperation among the researchres who aim the benefits of cancer patients.

We are looking forward to your participation in our Symposium.

Tadashi Kondo, MD, PhD Division of Rare Cancer Research,

National Cancer Center, Tokyo, Japan

Tadashi Kondo, MD, PhD

Chief, Division of Rare Cancer Research

National Cancer Center, Tokyo, Japan

Tadashi Kondo obtained his undergraduate degree in medicine (1992), and received his Ph.D. in Cell Biology (1992) from the Okayama University Medical School. After brief stints as an associate professor at the Oakyama University Medical School (Professor Masayoshi Namba Supervisor) and a postdoctoral fellow at the University of Michigan (Professor Samir Hanash Supervisor), he was appointed to the Cancer Proteomics Project at the National Cancer Center (NCC, Tokyo, Japan) in 2001 as a Section Head. He was promoted to Project Leader in the Proteome Bioinformatics Project (2006), Chief in Division of Pharmacoproteomics (2010), and Chief in Division of Rare Cancer Reseach (2014). He was appointed the director of the Institute of Tochigi Cancer Center (TCC, Tochigi, Japan) (2022) as a part of cross apointment system between NCC and TCC.

Current research in the Kondo lab and institute emphasizes the use of patient-derived cancer models and pharmaco-proteogenomics data to: 1) discover novel indication of existing anti-cancer drugs to rare cancers especially sarcomas; 2) develop predictive modalities complementary to cancer genome medicine; 3) create unique cancer models using patient-derived materials; and 4) promote transpational research, in which clinical questions lead novel collaborative studies between the researchers and clinicians. Research outcome that will be appreciated by the patients, their families, and medical staff is the final goal of his research.

Contact us >